During discharge teaching, a parent asks why the premature infant should get monthly injections of palivizumab. Which information should the nurse provide?

A. Palivizumab protects premature infants from respiratory syncytial virus (RSV) by providing passive immunity. Premature infants are at higher risk for severe RSV infection due to immature lungs and immune systems. B. Providing surfactant is a treatment for respiratory distress syndrome in premature infants, but palivizumab is not a surfactant. C. Preventing retinopathy of prematurity is achieved by careful oxygen management, not by palivizumab injections. D. Promoting neurological and physical development is not the purpose of palivizumab; its role is specifically RSV prevention.